Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1012Lung Neoplasms 769Small Cell Lung Carcinoma 159Breast Neoplasms 73Adenocarcinoma of Lung 68Neoplasms 67Colorectal Neoplasms 50NSCLC 49Melanoma 48Stomach Neoplasms 46Pleural Effusion, Malignant 46Pancreatic Neoplasms 45Brain Neoplasms 42Mesothelioma, Malignant 41Ovarian Neoplasms 32Prostatic Neoplasms 31Neoplasm Metastasis 31Head and Neck Neoplasms 30Mesothelioma 28Esophageal Neoplasms 27Carcinoma, Renal Cell 24Carcinoma 24Urinary Bladder Neoplasms 23Lung Diseases 22Colonic Neoplasms 22Thoracic Neoplasms 19Liver Neoplasms 19Thymoma 18Carcinoma, Hepatocellular 18Pleural Effusion 17

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nonsquamous Non-small Cell Lung Cancer × Thoracic × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡